Pediatrics

Your Article Summary

See Latest Articles

Intensified PEG-L-asparaginase and Antimetabolite-based Therapy for Treatment of Higher Risk Precursor-B Acute Lymphoblastic Leukemia
Journal of Pediatric Hematology/Oncology, 06/07/07

Salzer, W.L., et al. - The Pediatric Oncology Group 9203 pilot protocol was designed to determine the feasibility of delivering 29 biweekly doses of polyethylene glycol (PEG)-L-asparaginase, on a backbone of intensive multiagent antimetabolite-based consolidation and maintenance in higher risk B-precursor acute lymphoblastic leukemia. Between June 1992 and August 1993, 34 patients were enrolled on this limited institution pilot

Today in Clinical Pharmacology...keeping you current

Receive free subspecialty "5-minute updates" via email

Cardiac Safety of Methylphenidate Versus Amphetamine Salts in the Treatment of ADHD
Pediatrics, 07/02/09

Metformin for obesity in children and adolescents: a systematic review
Diabetes Care, 06/12/09

Empiric Antimicrobial Therapy for Pediatric Skin and Soft-Tissue Infections in the Era of Methicillin-Resistant Staphylococcus aureus
Pediatrics, 05/27/09

See All of Clinical Pharmacology

Today in Pediatric Heme/Oncology...keeping you current

Receive free subspecialty "5-minute updates" via email

Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia
British Journal of Haematology, 06/08/09

Clinical features of the most common fusion genes in childhood acute lymphoblastic leukemia
Medical Oncology, 06/05/09

Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin's lymphoma: an analysis of the European Group for Blood and Marrow Transplantation
Blood, 06/08/09

See All of Pediatric Heme/Oncology